Moderna is still fending off patent challenges over the lipid nanoparticle delivery system used in the company’s COVID-19 vaccine, Spikevax.
TANAKA Kikinzoku Kogyo K.K., which operates the TANAKA Precious Metals manufacturing business, announced that TANAKA developed gold shell nanoparticles1 that can be prepared in high concentrations using high dispersion stability.
Investigators at Washington University School of Medicine in St. Louis identified a compound that can help sensory neurons in the central nervous system to heal.
Moderna is seeking to invalidate two patents belonging to Arbutus Biopharma that deal with drug-delivery technology.
International biopharmaceutical firm Genevant Sciences announced a global collaboration and licensing deal with Takeda Pharmaceutical to create and commercialize new therapies that would hopefully treat two undisclosed types of rare liver diseases.
Biotech company Psycheceutical Inc. of Ft. Lauderdale, Fla., was issued two patents by the United States Patent and Trademark Office for what it calls a “precision duplicity” approach to delivering psychedelic drugs to patients.
Nanobiotix is developing a way for the company’s locally injected radioenhancer for solid tumors to treat metastasized cancers, in combination with checkpoint inhibitors, and also deliver results distally.
Paris-based Sanofi bought Cambridge, Massachusetts-based Tidal Therapeutics in a deal totaling $470 million.
Researchers are working on a type of vaccine technology using nanoparticles that is less expensive and does not need to be stored at very low temperatures compared to the mRNA technology used by BioNTech-Pfizer and Moderna to develop vaccines against Covid-19.
Moderna Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for the treatment of cystic fibrosis (CF).
